KR20050026806A - Cosmetic composition containing jujube extract - Google Patents
Cosmetic composition containing jujube extract Download PDFInfo
- Publication number
- KR20050026806A KR20050026806A KR1020030062963A KR20030062963A KR20050026806A KR 20050026806 A KR20050026806 A KR 20050026806A KR 1020030062963 A KR1020030062963 A KR 1020030062963A KR 20030062963 A KR20030062963 A KR 20030062963A KR 20050026806 A KR20050026806 A KR 20050026806A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- extract
- cosmetic composition
- composition
- sanjoin
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000002537 cosmetic Substances 0.000 title claims abstract description 24
- 240000008866 Ziziphus nummularia Species 0.000 title description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 28
- 238000009472 formulation Methods 0.000 claims abstract description 25
- 239000006071 cream Substances 0.000 claims abstract description 18
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 18
- 230000028327 secretion Effects 0.000 claims abstract description 14
- 230000037394 skin elasticity Effects 0.000 claims abstract description 14
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 12
- 206010022437 insomnia Diseases 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 11
- 239000000839 emulsion Substances 0.000 claims abstract description 6
- 239000006210 lotion Substances 0.000 claims abstract description 6
- 239000007921 spray Substances 0.000 claims abstract description 6
- 239000000499 gel Substances 0.000 claims abstract description 4
- 239000006072 paste Substances 0.000 claims abstract description 4
- 239000004094 surface-active agent Substances 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 239000000344 soap Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 23
- 101800005049 Beta-endorphin Proteins 0.000 claims description 16
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 claims description 16
- 230000004622 sleep time Effects 0.000 claims description 12
- 230000006872 improvement Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000003340 mental effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000002438 stress hormone Substances 0.000 abstract description 6
- 208000007443 Neurasthenia Diseases 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 230000036578 sleeping time Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 102400000748 Beta-endorphin Human genes 0.000 description 15
- 230000035882 stress Effects 0.000 description 14
- -1 dammarane glycoside Chemical class 0.000 description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- 238000002845 discoloration Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241001247821 Ziziphus Species 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229940010747 sodium hyaluronate Drugs 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 208000002720 Malnutrition Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 4
- 229960002456 hexobarbital Drugs 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000001071 malnutrition Effects 0.000 description 4
- 235000000824 malnutrition Nutrition 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 244000126002 Ziziphus vulgaris Species 0.000 description 3
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940079894 benzophenone-9 Drugs 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000004215 skin function Effects 0.000 description 3
- 229950011392 sorbitan stearate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- RUDVAOJNIYYYCQ-HUIKYQPJSA-N (1S,2R,5R,7S,10R,11R,14R,15S,16S,18R,20S)-2,6,6,10,16-pentamethyl-18-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.05,10.015,20]tricosane-7,16-diol Chemical compound CC(C)=C[C@H]1C[C@](C)(O)[C@@H]2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@@]33CO[C@@]2(C3)O1 RUDVAOJNIYYYCQ-HUIKYQPJSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000612118 Samolus valerandi Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- RUDVAOJNIYYYCQ-UHFFFAOYSA-N jujubogenin Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)(O)CC(C=C(C)C)OC33OCC21C3 RUDVAOJNIYYYCQ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- VGGSULWDCMWZPO-ODEMIOGVSA-N spinosin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=2C(=O)C=C(OC=2C=C1OC)C=1C=CC(O)=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VGGSULWDCMWZPO-ODEMIOGVSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- WZAXZHIVHPRTIU-UHFFFAOYSA-N 2''-O-(6-O-Feruloyl-beta-D-glucopyranoside)-Swertisin Natural products C1=C(O)C(OC)=CC(C=CC(=O)OCC2C(C(O)C(O)C(OC3C(OC(CO)C(O)C3O)C=3C(=C4C(=O)C=C(OC4=CC=3OC)C=3C=CC(O)=CC=3)O)O2)O)=C1 WZAXZHIVHPRTIU-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- TVUQUDJOLFMOKT-UHFFFAOYSA-N 3-(3-hydroxy-4-methoxybenzyl)-5,7-dihydroxy-6-methoxychroman-4-one Natural products CC(C)C1OC(C=C2)=CC=C2C=CNC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(N(C)C)CC1=CC=CC=C1 TVUQUDJOLFMOKT-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- TUWRBFMVJOJFCL-UHFFFAOYSA-N 4'-O-beta-D-Glucopyranoside,7-O-rutinoside-3',4',5,7-Tetrahydroxyflavone Natural products CC(=CC=CC(=C/C1CCC2C3(C)CCC(O)C(C)(C)C3CCC2(C)C14COC(=O)C4)C)C TUWRBFMVJOJFCL-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- FJSKSYVNULWVAZ-XTQSDGFTSA-N Jubanine B Chemical compound O=C1N\C=C\C(=C2)C(OC)=CC=C2OC2CCN(C(=O)C(CC=3C=CC=CC=3)NC(=O)C(CC=3C=CC=CC=3)N(C)C)C2C(=O)NC1CC1=CC=CC=C1 FJSKSYVNULWVAZ-XTQSDGFTSA-N 0.000 description 1
- SQHQDXGIJPHZRZ-AAWDLAKASA-N Jujuboside A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@@H](O)CO[C@H]1O[C@@H]1C(C)(C)[C@H](CC[C@@]2(C)[C@@]34C[C@]5([C@H]([C@@](C[C@@H](O5)C=C)(C)O)[C@H]4CC[C@H]42)OC3)[C@]4(C)CC1 SQHQDXGIJPHZRZ-AAWDLAKASA-N 0.000 description 1
- OAVAUZCEOWCYCC-BYHRGCEUSA-N Jujuboside B Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%10OC[C@@H](O)[C@H](O)[C@H]%10O)[C@H](O)[C@H](O)[C@H]1O OAVAUZCEOWCYCC-BYHRGCEUSA-N 0.000 description 1
- CJJVPWAZSXVOOK-IGTKYRGASA-N Jujuboside B Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@@H](O)CO[C@H]1O[C@@H]1C(C)(C)[C@H](CC[C@@]2(C)[C@@]34C[C@]5([C@H]([C@@](C[C@@H](O5)C=C)(C)O)[C@H]4CC[C@H]42)OC3)[C@]4(C)CC1 CJJVPWAZSXVOOK-IGTKYRGASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- DLQAPJHZUAUKEW-UHFFFAOYSA-N Mucronin D Natural products CCC(C)C1NC(=O)C2C(CCN2C(=O)C(CC(C)C)NC(=O)C(Cc3ccccc3)N(C)C)Oc4ccc(C=C/NC1=O)c(OC)c4 DLQAPJHZUAUKEW-UHFFFAOYSA-N 0.000 description 1
- OGCOHPMZUTVUAD-UHFFFAOYSA-N N-methyl-mauritine-F Natural products N1C(=O)C2N(C(=O)C(NC(=O)C(C)N(C)C)C(C)C)CCC2OC(C=C2)=CC=C2C=CNC(=O)C1CC1=CC=CC=C1 OGCOHPMZUTVUAD-UHFFFAOYSA-N 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229930183177 Sanjoinine Natural products 0.000 description 1
- 108010056226 Sanjoinine A Proteins 0.000 description 1
- RZPGHGRAYXXUEA-UHFFFAOYSA-N Sanjoinine B Natural products CNC(Cc1ccccc1)C(=O)NC2C(Oc3ccc(C=C/NC(=O)C(CC(C)C)NC2=O)cc3)C(C)C RZPGHGRAYXXUEA-UHFFFAOYSA-N 0.000 description 1
- FYTPTQFRMLVCGF-BHQDIPQRSA-N Sanjoinine D Natural products O=C(N[C@H]1[C@@H](C(C)C)Oc2ccc([C@@H](OC)CNC(=O)[C@H]([C@@H](CC)C)NC1=O)cc2)[C@H](N(C)C)Cc1ccccc1 FYTPTQFRMLVCGF-BHQDIPQRSA-N 0.000 description 1
- HIRIVYQNKNKCOO-UHFFFAOYSA-N Sanjoinine F Natural products CC(C)C(O)C1NC(=O)C(NC(=O)C(Cc2ccccc2)N(C)C)C(Oc3ccc(C=C/NC1=O)cc3)C(C)C HIRIVYQNKNKCOO-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- OAVAUZCEOWCYCC-NZTCAOINSA-N Zizyphussaponin III Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%10OC[C@@H](O)[C@H](O)[C@H]%10O)[C@H](O)[C@H](O)[C@@H]1O OAVAUZCEOWCYCC-NZTCAOINSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- VGGSULWDCMWZPO-UHFFFAOYSA-N flavoayamenin Natural products COC1=CC=2OC(C=3C=CC(O)=CC=3)=CC(=O)C=2C(O)=C1C1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O VGGSULWDCMWZPO-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KVKRFLVYJLIZFD-OPGZLHQPSA-N jujuboside A Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%11OC[C@@H](O)[C@H](O)[C@H]%11O)[C@H](O)[C@H](O)[C@H]1O KVKRFLVYJLIZFD-OPGZLHQPSA-N 0.000 description 1
- QCLBRNPQMDEDIM-UHFFFAOYSA-N jujuboside C Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(O)COC1OC1C(C)(C)C(CCC2(C)C34CC5(C(C(CC(O5)C=C(C)C)(C)O)C4CCC42)OC3)C4(C)CC1 QCLBRNPQMDEDIM-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- OGCOHPMZUTVUAD-NHFZPNTRSA-N mauritine A Chemical compound C([C@H]1C(=O)N\C=C/C2=CC=C(C=C2)O[C@H]2CCN([C@@H]2C(=O)N1)C(=O)[C@@H](NC(=O)[C@H](C)N(C)C)C(C)C)C1=CC=CC=C1 OGCOHPMZUTVUAD-NHFZPNTRSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- YDFMRHVTUVJMHS-XUTLUUPISA-N nummularin-b Chemical compound O1C(C=2)=CC=C(OC)C=2\C=C\NC(=O)C(C(C)CC)NC(=O)C2C1CCN2C(=O)C(NC(=O)C(CC=1C=CC=CC=1)N(C)C)CC1=CC=CC=C1 YDFMRHVTUVJMHS-XUTLUUPISA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 산조인 추출물 (Jujube extract)을 함유하는 피부 개선용 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition for skin improvement containing Sanjoin extract (Jujube extract).
피부는 외부로부터 신체를 보호하고, 체온조절, 피지분비, 모발생성 등의 항상성 유지에 필요한 기능들을 하고있다. 외부의 화학적, 물리적 자극, 스트레스, 불면증 및 영양결핍 등에 의해 피부가 그 기능의 균형을 잃게 되면 피부에 존재하는 세포의 활성이 저하되고, 구성 성분들이 본래의 안정된 구조를 유지하지 못하게 되어 피부의 탄력이 감소하고 피부의 윤택이 저하된다. 다시 말해서, 이러한 피부 기능의 불균형이 오래 지속되면, 피부 진피를 구성하는 섬유아세포 및 내피세포 등의 세포들과 콜라겐, 엘라스틴 및 파이브로넥틴과 같은 ECM (extracellular matrix) 구성 물질들이 비정상적으로 생성되거나 분해되며, 이것은 피부 전체의 구조에 영향을 주어, 궁극적으로 주름이 생기거나 탄력이 저하되는 등의 노화 현상이 촉진되는 것이다.The skin protects the body from the outside and functions to maintain homeostasis such as body temperature control, sebum secretion and hair growth. When the skin loses its function balance due to external chemical and physical stimuli, stress, insomnia and malnutrition, the cell's activity is reduced, and the components do not maintain their original stable structure. This reduces and reduces the skin's shine. In other words, if this skin function imbalance lasts a long time, abnormally generated or degraded cells such as fibroblasts and endothelial cells constituting skin dermis and extracellular matrix (ECM) components such as collagen, elastin and fibronectin This affects the structure of the entire skin, which ultimately promotes aging such as wrinkles or reduced elasticity.
외부로부터의 화학적, 물리적 자극, 스트레스, 불면증 및 영양결핍 등의 원인에 의해 우리 인체는 코티솔 (cortisol)이라는 스트레스 호르몬을 분비한다. 인체가 스트레스를 받게 되면 시상하부에서 우선 부신피질자극호르몬유리호르몬 (corticotropin releasing hormone, CRH)이 생성되고, 이 호르몬이 뇌하수체를 자극하여 부신피질자극호르몬 (adrenocorticotropic hormone, ACTH)의 생성을 촉진하고, 다시 이 호르몬이 부신피질을 자극하여 코티솔 (cortisol)이라는 부신피질호르몬을 분비시킨다. 이 호르몬은 인체의 여러 조직에서 글루코오스 신생합성 증가, 면역기능 저하, 성장호르몬 및 성호르몬 생성 억제, 혈중 콜레스테롤 증가 및 혈소판 응집 등에 작용한다.Our body secretes stress hormones called cortisol by chemical and physical stimuli, stress, insomnia and malnutrition from the outside. When the human body is stressed, corticotropin releasing hormone (CRH) is first produced in the hypothalamus, which stimulates the pituitary gland to promote the production of adrenocorticotropic hormone (ACTH). Again, this hormone stimulates the adrenal cortex and secretes an adrenal cortex hormone called cortisol. This hormone acts on the increase of glucose neosynthesis, decreased immune function, inhibition of growth hormone and sex hormone production, increased blood cholesterol and platelet aggregation in various tissues of the human body.
코티솔은 수면조절(도입)호르몬인 멜라토닌과 반대로 낮에는 생산량이 증가되며, 밤에는 생산량이 감소되는 것으로 알려져 있다. 보통 새벽 1-3시경 그 분비량이 최저이며, 아침 6시경부터 다시 혈중 농도가 증가하기 시작한다. 이처럼 코티솔은 수면에도 영향을 미치는 것으로 알려졌는데, 카페인 섭취 시 카페인이 부신피질을 자극하여 코티솔 분비량을 증가시킴으로써 수면을 방해하게 된다. 인체에서는 수면 시에 세포 재생력이 최고이고, 신진대사가 활발히 일어나며, 면역세포 또한 가장 활발하게 활동하고, 성장호르몬의 혈중 농도가 가장 높으며, 베타-엔도르핀 (β-endorphin)의 분비량이 증가한다.Cortisol, as opposed to melatonin, a sleep control hormone, is known to increase production during the day and decrease production at night. Usually its secretion is the lowest around 1-3 am, and blood levels begin to rise again around 6 am. Cortisol is also known to affect sleep, caffeine ingestion of caffeine stimulates the adrenal cortex and increases the amount of cortisol secretion interferes with sleep. In the human body, cell regeneration is best at sleep, metabolism is active, immune cells are also active, blood hormone levels are highest, and beta-endorphin secretion is increased.
베타-엔도르핀은 시상하부에서 생성되어지는 32개 아미노산 길이의 작은 단백질로 모르핀과 같은 마약의 기능과 유사한 기능을 가지고 있다. 물리적 또는 정신적 스트레스를 받을 때에 베타-엔도르핀이 생성되면, 기분이 좋아지고 통증을 완화된다. 심신이 평안하고 기분이 좋을 때에 베타-엔도르핀이 생성되면, 항암효과가 있으며 신진대사를 원활하게 하는 등의 작용을 한다.Beta-Endorphin is a small 32-amino acid protein produced in the hypothalamus that is similar in function to drugs like morphine. When beta-endorphin is produced during physical or mental stress, it improves mood and relieves pain. When beta-endorphin is produced when the mind and body are calm and comfortable, it has an anticancer effect and smoothes metabolism.
이처럼 수면으로부터 얻어지는 효과를 통하여 건강한 피부를 유지할 수 있을 것으로 판단된다.It is believed that healthy skin can be maintained through the effects obtained from sleep.
한편, 산조인은 불면증, 신경쇠약, 수면 시 식은땀이 흐르는 증상 및 신경성 스트레스 등에 효과가 있는 것으로 알려져 있으며, 대한민국 특허출원 제 2001-36035 호 "생약제를 이용한 성장 촉진용 식품"에서는 산조인을 사료와 함께 자돈에 섭취시키면 체중 증가량이 향상된다고 개시하였다. 이처럼 산조인은 지금까지 식품, 생약제 및 사료 등에서는 널리 사용되어 왔으나 이를 화장료 조성물에 적용하여 화학적 또는 물리적 스트레스에 의한 피부 탄력 및 윤택의 감소를 개선함으로써 피부의 건강에 도움을 주는 목적으로 사용되지는 않았다.On the other hand, Sanjoin is known to be effective in insomnia, nervous breakdown, symptoms of cold sweating and nervous stress during sleep, and in Korea Patent Application No. 2001-36035 "Food for promoting growth using herbal medicines" Sanjoin with food It is disclosed that the weight gain is improved when ingested in piglets. As such, Sanjoin has been widely used in foods, herbal medicines, and feeds, but it has not been used for the purpose of helping skin health by improving the reduction of skin elasticity and moisture caused by chemical or physical stress by applying it to cosmetic compositions. .
본 명세서 전체에 걸쳐 다수의 특허 문헌 및 논문이 참조되고 그 인용이 표시되어 있다. 인용된 특허 문헌 및 논문의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.Throughout this specification, numerous patent documents and articles are referenced and their citations are indicated. The disclosures of cited patent documents and articles are incorporated herein by reference in their entirety, so that the level of the technical field to which the present invention belongs and the contents of the present invention are more clearly explained.
본 발명자들은 외부로부터의 화학적, 물리적 자극, 스트레스, 불면증, 영양결핍 등의 원인에 의해 탄력 및 윤택이 저하된 피부를 건강한 상태로 유지시키는 방법에 관하여 예의 연구 노력한 결과, 산조인 추출물이 스트레스 호르몬인 코티솔의 분비를 억제하고 혈중 내 콜레스테롤의 함량을 낮추며 베타-엔도르핀의 분비를 촉진하고 수면 시간을 연장시키는 효과가 있음을 발견하였으며, 이를 화장료에 사용하면 피부의 기능 저하를 개선하여 피부탄력 및 피부윤택이 증진되는 것을 확인하여 본 발명을 완성하였다. The present inventors have diligently researched how to maintain the skin in which the elasticity and the moisture are deteriorated due to chemical, physical stimulation, stress, insomnia, malnutrition, etc. from the outside, and the sanjoin extract is a stress hormone cortisol. It has been found to have an effect of inhibiting secretion of blood, lowering the amount of cholesterol in the blood, promoting the secretion of beta-endorphin, and prolonging the sleep time. Confirmed to be enhanced to complete the present invention.
따라서, 본 발명의 목적은 산조인 추출물을 유효 성분으로 함유하는 피부 개선용 화장료 조성물을 제공하는 데 있다. Accordingly, it is an object of the present invention to provide a cosmetic composition for skin improvement comprising the acid extract as an active ingredient.
본 발명의 다른 목적 및 이점은 하기의 실시예 및 청구범위에 의해 보다 명확하게 된다. Other objects and advantages of the present invention will become apparent from the following examples and claims.
본 발명은 산조인 추출물을 함유하는 피부 개선용 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition for skin improvement containing the acid extract.
본 발명의 조성물은 산조인 추출물을 유효성분으로 함유하는 것을 특징으로 한다.The composition of the present invention is characterized by containing the acid extract as an active ingredient.
본 발명의 조성물에서 유효성분으로 이용되는 산조인 (酸棗仁)은 산대추 (일명: 멧대추) (Zizyphus vulgaris Lamarck var. spinosus Bunge)의 씨앗을 의미하며, 산대추는 국내에서 일반적으로 재배 및 생산되는 대추 (Zizyphus vulgaris Lamarck var. inermis Bunge)와 그 종류 및 효능에는 차이가 있다.Sanjoin (酸棗仁) used as an active ingredient in the composition of the present invention refers to the seeds of wild jujube (aka: jujube jujube) ( Zizyphus vulgaris Lamarck var. Spinosus Bunge), jujube jujube is commonly grown and produced in Korea ( Zizyphus vulgaris Lamarck var. Inermis Bunge) and its type and efficacy are different.
산대추는 낙엽관목으로서 키는 2-4 m 정도로 자라며 어린가지는 녹색이고 가지에는 바늘모양과 반곡형 (反曲形)의 가시가 대생 (對生)하며 잎은 호생이며 난형이고 잔거치가 있으며 윤채를 띤다. 대추나무의 잎새와 비슷하나 좀 작다. 5-6 월에 황록색의 작은 꽃이 되고 과실은 9-10 월에 성숙한다. 대추와는 달리 이 식물의 종자는 장타원형이며 색은 엷은 적갈색이며 과육이 거의 없고 과실은 얇은 과피를 지니고 전부가 종자로 되어 있으며 과실의 길이는 0.8-1 cm 내외이고 지름은 이보다 더 짧다. 이 식물의 잎은 산조엽 (酸棗葉)이라고 하고 뿌리 껍질은 산조근피 (酸棗根皮)라 해서 약용한다. Mountain jujube is a deciduous shrub, grows about 2-4 m in height, young branches are green, and branches have needle-shaped and semi-curved spines. It takes Similar to the leaves of jujube tree, but a little smaller. Yellow-green small flowers in May-June, fruits mature in September-October. Unlike jujube, the seeds of the plant are long oval, light reddish brown, almost without flesh, fruit with thin skin, whole with seeds, length of fruit is about 0.8-1 cm, diameter is shorter than this. The leaves of this plant are called Sanjo Leaf, and the root bark is medicinal called Sanjo Root Bark.
특히, 멧대추의 종인(種仁)은 산조인(酸棗仁)이라 해서 고래로부터 정신과 영역의 명약으로 전해져 내려오고 또 잘 쓰여지고 있다. 산조인은 가을철에 과실을 따서 하루동안 물에 담궜다가 과육을 제거한 뒤 과실 껍질을 부수어 종인(種仁)을 빼내 햇빛에 말린 것인데 이것을 그대로 약용할 수도 있으며 때로는 초(炒)해서 쓰기도 한다.Particularly, the species of medulled jujube () 仁) is called Sanjoin (酸棗仁) and has been handed down from the whale as a psychiatric medicine and has been used well. Sanjoin is picking fruits in autumn and soaking them in water for one day, removing the flesh, and then breaking the skin of the fruit to remove Jongin (種 仁) and dried it in the sun.
산조인의 성분으로는 시클로펩타이드계의 알칼로이드인 산조이닌 (sanjoinine) A, B, D, F 및 G, 마우리틴 (mauritine) A, 무크로닌 (mucronin) D, 주바닌 (jubanine) A, B가 있고 펩타이드계 알칼로이드로서 산조이닌 (sanjoinine), 아포핀 (aporphine)계 알칼로이드로서는 지지퍼신 (zizyphusine) 등이 있다. 한편 에벨린락톤 (ebelinlactone)은 가수분해되어 주주보게닌 (jujubogenin)이 생성된다. 주주보게닌은 주주보사이드 (jujuboside) A, B 와 더불어 담마란 글리코사이드 (dammarane glycoside)에 속하며 그 작용도 기대되고 있다. 과실에는 플라본 글리코사이드 (flavone glycoside)가 0.06% 함유되며 0.35%의 쿠마린 유도체 (coumarin derivatives)도 들어 있다. 기타 성분으로 베툴산 베툴린 (betulic acid betulin), 스피노신-6-p-쿠마릴 스피노신 (spinosin-6-p-coumaryl spinosin), 6-페룰로일 스피노신 (6-feruloyl spinosin) 등이 함유되어 있어 그 성분의 다양성이 엿보인다 (생화학뉴스, 1990;10(4):239-245).The components of the sanjoin include the alkaloids of the cyclopeptides, sanjoinine A, B, D, F and G, mauritine A, mucronin D, jubanine A and B. Examples of the peptide-based alkaloids include sanjoinine, and apophine-based alkaloids such as zizyphusine. Meanwhile, ebelinlactone is hydrolyzed to produce jujubogenin. Jujubogenin belongs to the dammarane glycoside in addition to jujuboside A and B, and its action is also expected. The fruit contains 0.06% flavone glycoside and 0.35% coumarin derivatives. Other ingredients include betulic acid betulin, spinocin-6-p-coumaryl spinosin, and 6-feruloyl spinosin. It contains a variety of ingredients (Biochemistry News, 1990; 10 (4): 239-245).
중국의 고전인 본초강목에는 열매에서 얻어지는 종인은 신경강장제로 쓰이며 실면 (失眠)을 고치고 위에도 좋은 약효를 제공할 뿐 아니라 진정약으로서의 성과를 지닌다고 하였다. 또 종인의 생품 (生品)은 간장의 강화약에 쓰이며 또한 보담 (補膽)의 효과도 있다고 했다. 따라서 불면노번은 물론이고 신경과민에도 좋은 진정효과를 지닌다고 하였다.The Chinese classic herbaceous hardwood, the species obtained from the fruit, is used as a nerve tonic, it repairs cotton, and provides good effects on the stomach. In addition, the raw material of the servant (生 品) is used for the fortification of soy sauce, and also has the effect of bodam (補 膽). Therefore, insomnia as well as insomnia has good sedative effect.
본 발명에서 이용되는 산조인 추출물은, 당업계에 공지된 다양한 방법을 통해 얻어질 수 있고, 바람직하게는 (a) 물, (b) 탄소수 1-4의 무수 또는 함수 저급 알코올 (예: 메탄올, 에탄올, 프로판올, 부탄올 등), (c) 아세톤, (d) 에틸 아세테이트, (e) 클로로포름 또는 (f) 1,3-부틸렌글리콜을 추출 용매로 하여 상기 산조인으로부터 얻은 것이다. 보다 바람직하게는, 추출 용매는 에탄올이며, 가장 바람직하게는 약 70% 에탄올이다. 추출의 재료가 되는 산조인은 이를 건조하여 사용하거나 또는 그대로 사용할 수 있으며, 바람직하게는 건조하여 사용하는 것이다. 건조법으로는 자연 건조 또는 열풍 건조법을 이용할 수 있다.The acid extract used in the present invention may be obtained through various methods known in the art, and preferably includes (a) water, (b) anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms (eg, methanol, ethanol). , Propanol, butanol, and the like), (c) acetone, (d) ethyl acetate, (e) chloroform or (f) 1,3-butylene glycol as an extraction solvent. More preferably, the extraction solvent is ethanol, most preferably about 70% ethanol. The acid join which becomes the material of extraction can be used by drying it, or it can be used as it is, Preferably it is used by drying. As a drying method, natural drying or a hot air drying method can be used.
본 발명의 하기 특정 제조예를 참조하여 산조인 추출물의 제조방법을 설명하면 다음과 같다: 산조인을 정제수로 세척한 후 건조하고 작은 조각으로 파쇄한 뒤, 여기에 그 건조 중량의 1-10배의 저급알코올을 첨가한다. 일정온도에서 수 일간 추출한 후 여과포로 여과하였다. 다시 여과지로 여과한 다음, 회전감압 증발기로 건조한다. 건조된 산조인 추출물 파우더를 글리콜, 바람직하게는 부틸렌 글리콜에 용해하여 사용한다.Referring to the preparation method of the acid extract with reference to the following specific preparation example of the present invention as follows: The acid join is washed with purified water and then dried and crushed into small pieces, which is 1-10 times lower than its dry weight Add alcohol. After extracting for several days at a constant temperature, it was filtered through a filter cloth. Filter again with filter paper and dry with a rotary evaporator. The dried sanjoin extract powder is used by dissolving in glycol, preferably butylene glycol.
한편, 본 발명의 추출물은 상기한 추출용매 뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 산조인 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다.On the other hand, it is apparent to those skilled in the art that the extract of the present invention can be obtained not only the above-described extraction solvent, but also an acid crude extract having substantially the same effect using other extraction solvents.
또한, 본 발명의 추출물은 상술한 추출 용매에 의한 추출물 뿐 만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 산조인 추출물에 포함되는 것이다.In addition, the extract of the present invention includes not only the extract by the above-mentioned extraction solvent, but also an extract that has undergone a conventional purification process. Obtained by various additional purification methods, such as, for example, separation using ultrafiltration membranes having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). The fraction is also included in the acid extract of the present invention.
본 발명의 산조인 추출물은 감압 증류, 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.Sanjoin extract of the present invention may be prepared in a powder state by an additional process such as vacuum distillation, freeze drying or spray drying.
본 발명의 산조인 추출물을 함유하는 화장료 조성물은 외적요인에 의해 악화된 피부의 기능을 개선한다.The cosmetic composition containing the sanjoin extract of the present invention improves the function of the skin worsened by external factors.
외적요인 특히, 스트레스, 불면증 및 신경쇠약 등의 정신적 요인에 의해 피부가 그 기능의 균형을 잃게 되면, 피부 진피를 구성하는 섬유아세포 및 내피세포 등의 세포들과 ECM (extracellular matrix) 구성 물질들이 비정상적으로 생성되거나 분해되어, 궁극적으로 주름이 생기거나 탄력이 저하되는 등의 노화 현상이 촉진된다.External factors, especially when the skin is unbalanced due to mental factors such as stress, insomnia and nervous breakdown, cells such as fibroblasts and endothelial cells and extracellular matrix (ECM) components that make up the dermis are abnormal It is generated or decomposed, which ultimately promotes aging such as wrinkles or reduced elasticity.
본 발명의 산조인 추출물은 (ⅰ) 상기의 외부요인에 의해 분비되는 스트레스 호르몬인 코티솔의 분비 억제, (ⅱ) 콜레스테롤의 함량 감소, (ⅲ) 베타-엔도르핀의 생성 촉진, (ⅳ) 수면 시간의 연장 효과가 있으며, 상기의 효과 또는 이의 조합 (combination)에 의해, 피부의 기능에 불균형이 초래되는 것을 예방 및 개선하고, 결과적으로 피부의 기능을 유지시켜 피부탄력 및 피부윤택을 증진한다.Sanjoin extract of the present invention (i) inhibits the release of cortisol, a stress hormone secreted by the external factors, (ii) decreases the content of cholesterol, (i) promotes the production of beta-endorphin, (i) prolongs sleep time There is an effect, and by the above effects or a combination thereof, it prevents and improves the imbalance in the function of the skin, and consequently maintains the function of the skin, thereby promoting skin elasticity and skin benefits.
따라서, 본 발명에서 용어 "악화된 피부"란 외적요인 특히 스트레스, 불면증 및 신경쇠약 등의 정신적 요인에 의해 피부의 기능에 불균형이 초래되어 그 기능이 저하된 피부를 의미한다. 본 발명에서 용어 "피부 개선"은 상기 피부의 불균형을 예방 및 개선하는 것을 의미하며, 피부탄력 또는 피부윤택이 증진되는 것을 포함한다.Therefore, in the present invention, the term "aggravated skin" refers to skin having an imbalance in the function of the skin due to external factors, in particular, mental factors such as stress, insomnia, and nervous breakdown, and the function of which is degraded. The term "skin improvement" in the present invention means to prevent and improve the imbalance of the skin, including the enhancement of skin elasticity or skin shine.
본 발명의 바람직한 구현예에 따르면, 산조인 추출물의 함량은 조성물 총 중량에 대하여 0.0001-5.0 중량%이다.According to a preferred embodiment of the present invention, the content of the acid extract is 0.0001-5.0% by weight relative to the total weight of the composition.
본 발명의 화장품 조성물에 포함되는 성분은 유효 성분으로서의 산조인 추출물 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 함유, 그리고 담체를 포함한다.The components included in the cosmetic composition of the present invention include components conventionally used in cosmetic compositions in addition to the acidic extract as the active ingredient, and include, for example, conventional contents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, and Carrier.
본 발명의 피부탄력 및 피부윤택 증진용 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The skin elasticity and skin-enhancing composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps , Surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, sprays, and the like, but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
본 발명에 따르면, 본 발명은 불면증, 신경쇠약, 수면 시 식은땀이 흐르는 증상 및 신경성 스트레스 등에 효과가 있는 것으로 알려져 있는 산조인의 추출물을 화장료에 사용함으로써 외부요인에 의해 발생하는 피부기능의 불균형을 예방 및 개선하여 피부 탄력 및 윤택을 증진한다.According to the present invention, the present invention prevents the imbalance of skin function caused by external factors by using an extract of Sanjoin, which is known to be effective in insomnia, nervous breakdown, symptoms of cold sweating during sleep, and nervous stress. And improve skin elasticity and shine.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, it is to those skilled in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. Will be self-evident.
제조예 1: 산조인 추출물 제조방법Preparation Example 1: Sanjoin Extract Preparation Method
산조인을 정제수로 세척한 후 건조하고 작은 조각으로 파쇄한 뒤, 여기에 그 건조 중량의 1-10배의 70% 저급알코올을 첨가하였다. 15-35℃에서 5일간 추출한 후 300메쉬 여과포로 여과하였다. 다시 와트만 5번 여과지로 여과한 다음, 회전감압 증발기로 건조하여, 건조 중량 47 g/㎏을 얻었다. 건조된 산조인 추출물 파우더를 50% 1,3-부틸렌 글리콜에 용해하여 사용하였다.The acid join was washed with purified water, dried and broken into small pieces, and then 1-10 times 70% lower alcohol of the dry weight was added thereto. After extraction for 5 days at 15-35 ℃ filtered with 300 mesh filter cloth. The filter was again filtered through Whatman No. 5 filter paper, and then dried using a rotary evaporator to obtain a dry weight of 47 g / kg. The dried acid extract powder was dissolved in 50% 1,3-butylene glycol and used.
실험예 1: 산조인 추출물이 쥐의 코티솔, 베타-엔도르핀 및 혈액 내의 콜레스테롤 수준에 미치는 효과Experimental Example 1: Effect of Sanjoin Extract on Cortisol, Beta-Endorphin and Cholesterol Levels in Rats
제조예 1의 산조인 추출물이 코티솔 분비, 베타-엔도르핀 분비 및 콜레스테롤 수준에 영향을 주어, 쥐에서 스트레스에 대한 순응 및 스트레스 완화 효과를 나타내는지 확인하였다. 쥐를 고정시켜 움직이지 못하게 하면, 쥐는 스트레스로 인하여 스트레스 호르몬인 코티솔 및 베타-엔도르핀의 분비가 촉진되며, 혈액 내의 콜레스테롤 함량이 증가하는 것으로 알려져 있다.Sanjoin extract of Preparation Example 1 affected the cortisol secretion, beta-endorphin secretion and cholesterol levels, it was confirmed that the rats exhibited the stress adaptation and stress relief effect. When the rat is immobilized and immobilized, the rat promotes the secretion of stress hormones cortisol and beta-endorphin due to stress, and it is known that the cholesterol content in the blood increases.
제조예 1의 산조인 추출물을 쥐에 10 ㎎/㎏ 씩 경구 투여하고 쥐를 16 시간 동안 고정시켰다. 16 시간 후 실험 동물의 코티솔, 베타-엔도르핀 및 콜레스테롤 양을 측정하였다. 그 결과는 하기 표 1에 나타나 있다.Sanjoin extract of Preparation Example 1 was orally administered to mice at 10 mg / kg and the mice were fixed for 16 hours. After 16 hours, the amounts of cortisol, beta-endorphin and cholesterol of the experimental animals were measured. The results are shown in Table 1 below.
상기 표 1의 결과로부터 알 수 있듯이, 산조인 추출물의 투여군에서는 산조인 추출물의 투여 없이 스트레스만을 가한 대조군에 비해 베타-엔도르핀의 생성량이 35.4% 증가하였으며, 코티솔 및 혈중 콜레스테롤은 각각 18.8%, 39.3% 감소하였다. 따라서 산조인 추출물이 과도한 스트레스에 효과적으로 대응할 수 있도록 하는, 즉 베타-엔도르핀의 생성량을 증가시키며, 코티솔 및 콜레스테롤 수치는 감소시키는 효과가 있음을 알 수 있다.As can be seen from the results of Table 1, the beta-endorphin production was increased by 35.4%, cortisol and blood cholesterol decreased by 18.8% and 39.3%, respectively, in the administration group of the Sanjoin extract compared to the control group without the administration of the Sanjoin extract. . Therefore, it can be seen that the Sanjoin extract can effectively cope with excessive stress, that is, increase the production of beta-endorphin, and reduce cortisol and cholesterol levels.
실험예 2: 산조인 추출물의 수면 시간 연장 효과Experimental Example 2: Sleep Time Extension Effect of Sanjoin Extract
제조예 1의 산조인 추출물이 쥐의 헥소바비탈 (hexobarbital)에 의하여 유도된 수면 시간 연장에 주는 효과를 측정하였다.The effect of Sanjoin extract of Preparation Example 1 on the prolongation of sleep time induced by hexobbital in mice was measured.
각 군 당 10 마리의 웅성 쥐 (20-30g)에 공지의 수면제인 헥소바비탈을 체중 1 ㎏당 50 ㎎ 씩 복강 주사한 후, 제조예 1에서 얻은 산조인 추출물을 체중 1 ㎏ 당 각각 5 ㎎, 10 ㎎, 20 ㎎ 씩 주사하여 수면 시간 연장효과를 조사하였다. 헥소바비탈만을 복강 주사하고, 산조인 추출물을 주사하지 않은 것을 대조군으로 하였다. 그 결과는 하기 표 2에 나타나 있다.10 male rats (20-30 g) in each group were intraperitoneally injected with a well-known sleeping agent hexobarbital at 50 mg / kg of body weight, and the sanjoin extract obtained in Preparation Example 1 was 5 mg / kg, respectively, 10 mg and 20 mg were injected to investigate the effect of prolonging sleep time. Only hexobarbital was injected intraperitoneally, and the sanjoin extract was not injected as a control. The results are shown in Table 2 below.
상기 결과로부터 알 수 있듯이, 산조인 추출물은 공지의 수면제인 헥소바비탈에 의하여 유도된 쥐의 수면 시간을 연장시키는 효과를 나타내었으며, 5 ㎎/㎖ 및 10 ㎎/㎖의 농도에서는 수면 시간이 농도 의존적으로 증가하였으나 그 이상의 농도에서는 더 이상의 수면 시간 연장효과를 보이지는 않았다.As can be seen from the above results, Sanjoin extract showed the effect of prolonging the sleep time of rats induced by the known sleeping agent hexobarbital, and the concentration of sleep time was concentration-dependent at concentrations of 5 mg / ml and 10 mg / ml. At higher concentrations, the effect of prolonging sleep time did not appear.
상기 실험예들을 근거로 외부로부터의 화학적, 물리적 자극, 스트레스, 불면증, 영양결핍 등의 원인에 의해 거칠어진 피부, 탄력 및 윤택이 저하된 피부를 건강한 상태로 유지시켜 줄 수 있는 산조인 추출물을 포함하는 여러 가용화 제형과 유화제형의 화장료 조성을 제시한다. 아래와 같은 제형예에서 이를 상세히 설명하지만 본 발명의 조성물이 하기 예에만 한정되는 것은 아니다.On the basis of the experimental examples, the skin roughened by the causes of chemical, physical stimulation, stress, insomnia, malnutrition, etc. from the outside, including a sanjoin extract that can maintain a healthy state of reduced skin and elasticity and moisture Several solubilized formulations and emulsifier formulations are presented. Although this is described in detail in the following formulation example, the composition of the present invention is not limited only to the following examples.
제형예 1: 유연화장수 (스킨로션)Formulation Example 1: Softener (Skin Lotion)
하기의 표 3과 같이 산조인 추출물을 함유하는 유연화장수를 통상의 방법에 따라 제조하였다.A flexible longevity containing the acid extract as shown in Table 3 below was prepared according to a conventional method.
제형예 2: 수렴화장수Formulation Example 2: Converging Cosmetic Water
하기의 표 4와 같이 산조인 추출물을 함유하는 수렴화장수를 통상의 방법에 따라 제조하였다.As shown in Table 4 below, astringent cosmetic water containing an acid extract was prepared according to a conventional method.
제형예 3: 영양화장수Formulation Example 3: Nutrients
하기의 표 5와 같이 산조인 추출물을 함유하는 영양화장수를 통상의 방법에 따라 제조하였다.Nutrients containing Sanjoin extract as shown in Table 5 below were prepared according to a conventional method.
제형예 4: 영양크림Formulation Example 4: Nutrition Cream
하기의 표 6과 같이 산조인 추출물을 함유하는 영양크림을 통상의 방법에 따라 제조하였다.A nutritive cream containing an acid extract, as shown in Table 6 below, was prepared according to a conventional method.
제형예 5: 맛사지 크림Formulation Example 5: Massage Cream
하기의 표 7과 같이 산조인 추출물을 함유하는 맛사지 크림을 통상의 방법에 따라 제조하였다.A massage cream containing an acid extract, as shown in Table 7 below, was prepared according to a conventional method.
제형예 6: 에센스Formulation Example 6: Essence
하기의 표 8과 같이 산조인 추출물을 함유하는 에센스를 통상의 방법에 따라 제조하였다.Essences containing the acid extract as shown in Table 8 below was prepared according to a conventional method.
제형예 7: 팩Formulation Example 7: Pack
하기의 표 9와 같이 산조인 추출물을 함유하는 팩을 통상의 방법에 따라 제조하였다.As shown in Table 9 below, a pack containing an acid extract was prepared according to a conventional method.
실험예 3: 피부탄력 및 피부윤택 효과 측정Experimental Example 3: Measurement of Skin Elasticity and Skin Moisturizing Effect
본 발명의 산조인 추출물을 포함하는 화장료 조성물을 인체에 적용하고 피부탄력 및 피부윤택 증감 정도를 평가하였다.The cosmetic composition comprising the extract of Sanjoin of the present invention was applied to the human body and the skin elasticity and the degree of skin moisturization were evaluated.
30-40 대의 건강한 여성 20명을 대상으로 상기 제형예 4에서 제조한 산조인 추출물을 포함한 크림 (실시예) 및 산조인 추출물을 정제수로 대체한 크림 (비교예)을 각각 안면 우측 및 좌측에 매일 아침, 저녁으로 2회, 0.2 g씩 얼굴 피부에 도포하고, 약 2개월 경과 후 얼굴 피부의 탄력 및 윤택 정도를 스스로 평가하도록 하였다. 또한, 기기 Cutometer SEM 575를 사용하여 피부탄력을, 기기 Colorimeter Minolta CR-300을 사용하여 피부윤택을 측정하였다. 상기 실험 결과는 표 10에 나타나 있다. Each morning, 20 healthy females in their 30s and 40s were treated with cream (Example) and Sanjoin extract prepared in Formulation Example 4 and the cream (Comparative Example) replaced with purified water each morning on the right and left sides of the face, respectively. Two evenings, 0.2 g each was applied to the facial skin, and after about two months, the elasticity and shine of the facial skin were evaluated by themselves. In addition, skin elasticity was measured using the instrument Cutometer SEM 575, and skin moisture was measured using the instrument Colorimeter Minolta CR-300. The experimental results are shown in Table 10.
산조인 추출물이 포함된 크림 (실시예)을 사용할 경우에 산조인 추출물을 포함하지 않은 크림 (비교예)에 비해 피부탄력 및 피부윤택이 보다 증가됨을 알 수 있었다.When using the cream containing the extract Sanjoin (Example), it was found that the skin elasticity and skin benefits are increased compared to the cream (Comparative Example) not containing the extract Sanjoin.
실험예 4: 제형의 안정성 시험Experimental Example 4: Stability Test of the Formulation
본 발명의 산조인 추출물을 포함하는 화장료 조성물의 제형의 안정성 시험을 위하여, 상기 표 4에서 제형한 산조인 추출물을 포함한 크림 (실시예) 및 산조인 추출물을 정제수로 대체한 크림 (비교예)을 45℃로 일정하게 유지되는 항온조와 4℃로 일정하게 유지되는 완전히 차광된 냉장고 내에서 불투명 초자 용기에 담아 12주 동안 보관한 후, 분리 정도 및 변색 정도를 비교 측정하였다. 제형의 분리 및 변색 정도는 다음의 6등급으로 분류하여 평가하였다.In order to test the stability of the formulation of the cosmetic composition comprising the acid extract of the present invention, the cream containing the extract of Sanjoin formulated in Table 4 (Example) and the cream (Comparative Example) replacing the sanjoin extract with purified water to 45 ℃ After keeping for 12 weeks in an opaque glass container in a constant-temperature bath and a completely shaded refrigerator maintained at 4 ℃ constant, the degree of separation and discoloration was measured. The degree of separation and discoloration of the formulation was evaluated by classifying into the following six grades.
* 제형의 변색 평가 기준* Evaluation criteria for discoloration of formulation
0 : 변화 없음 1: 극히 조금 분리 (변색)0: no change 1: very little separation (discoloration)
2: 조금 분리 (변색) 3: 조금 심하게 분리 (변색)2: little separation (discoloration) 3: little separation (discoloration)
4: 심하게 분리 (변색) 5: 극히 심하게 분리 (변색)4: severely separated (discolored) 5: extremely severely separated (discolored)
상기 실험 결과는 하기 표 11에 나타나 있다.The experimental results are shown in Table 11 below.
상기 표 11에 나타난 바와 같이, 실시예 및 비교예의 화장료 조성물은 변색 및 분리현상이 일어나지 않아 제형의 안정성에는 이상이 없음을 알 수 있었다.As shown in Table 11, the cosmetic compositions of Examples and Comparative Examples did not occur discoloration and separation did not occur in the stability of the formulation.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that the specific technology is merely a preferred embodiment, and the scope of the present invention is not limited thereto. Therefore, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
이상에서 상세히 설명하였듯이, 본 발명은 산조인 추출물을 포함하는 화장료 조성물을 제공한다. 본 발명의 산조인 추출물은 스트레스 호르몬의 일종인 코티솔의 분비를 억제하고 혈중 콜레스테롤을 감소시키며 베타-엔도르핀의 분비를 촉진하고 수면 시간을 연장시키는 효과를 통하여 피부기능의 불균형을 예방 및 개선하여, 결과적으로 피부탄력 및 피부윤택을 증진시키데 매우 탁월한 효과가 있다. 또한, 산조인 추출물을 포함하는 화장료 조성물은 안정성에도 문제가 없다.As described in detail above, the present invention provides a cosmetic composition comprising the acid extract. Sanjoin extract of the present invention prevents and improves the imbalance of skin function through the effect of inhibiting the secretion of cortisol, a type of stress hormone, reducing blood cholesterol, promoting the secretion of beta-endorphin, and prolonging sleep time. It is very effective in enhancing skin elasticity and skin shine. In addition, the cosmetic composition containing an acid extract is not a problem in stability.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030062963A KR20050026806A (en) | 2003-09-09 | 2003-09-09 | Cosmetic composition containing jujube extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030062963A KR20050026806A (en) | 2003-09-09 | 2003-09-09 | Cosmetic composition containing jujube extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20050026806A true KR20050026806A (en) | 2005-03-16 |
Family
ID=37384455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030062963A KR20050026806A (en) | 2003-09-09 | 2003-09-09 | Cosmetic composition containing jujube extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20050026806A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106924592A (en) * | 2017-03-28 | 2017-07-07 | 上海大学 | A kind of Chinese medicine preparation for tranquilizing soporific strengthen immunity and preparation method thereof |
US9956242B2 (en) | 2011-11-30 | 2018-05-01 | Ministry Of Food And Drug Safety | Pharmaceutical composition for prevention or treatment of cognitive function disorders comprising spinosin |
KR20190031987A (en) | 2017-09-19 | 2019-03-27 | 학교법인혜화학원 | Pharmaceutical Compositions Comprising Zizyphus jujuba var. spinosa Composite oil Having Anti-atopy |
CN115715747A (en) * | 2022-11-30 | 2023-02-28 | 水羊化妆品制造有限公司 | Application of dark green tea polysaccharide in preparation of anti-pressure product |
-
2003
- 2003-09-09 KR KR1020030062963A patent/KR20050026806A/en not_active Application Discontinuation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9956242B2 (en) | 2011-11-30 | 2018-05-01 | Ministry Of Food And Drug Safety | Pharmaceutical composition for prevention or treatment of cognitive function disorders comprising spinosin |
CN106924592A (en) * | 2017-03-28 | 2017-07-07 | 上海大学 | A kind of Chinese medicine preparation for tranquilizing soporific strengthen immunity and preparation method thereof |
KR20190031987A (en) | 2017-09-19 | 2019-03-27 | 학교법인혜화학원 | Pharmaceutical Compositions Comprising Zizyphus jujuba var. spinosa Composite oil Having Anti-atopy |
CN115715747A (en) * | 2022-11-30 | 2023-02-28 | 水羊化妆品制造有限公司 | Application of dark green tea polysaccharide in preparation of anti-pressure product |
CN115715747B (en) * | 2022-11-30 | 2024-07-09 | 水羊化妆品制造有限公司 | Application of black tea polysaccharide in preparation of compression-resistant product |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101393007B1 (en) | Cosmetic Composition for Skin-aging Protection and Wrinkle Improvement Comprising the Extract of Nephelium lappaceum and Litchi chinensis sonn as Active Ingredient | |
KR102041927B1 (en) | A composition for preventing or improving skin wrinkle comprising herb extracts fermentation products thereof | |
KR20200057677A (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR20140115400A (en) | Composition of scalp care for prevention of depilation and improvement of hair growth comprising Rhus javanica L. Extracts | |
KR20160082138A (en) | Composition for improving skin condition comprising extract of hydrangea serrata | |
KR101312965B1 (en) | The cosmetic composition for anti-wrinkle comprising the mixture of extract of Allium cepa, Symphytum officinale, Eclipta prostrate, and Theobroma cacao | |
KR20070102911A (en) | Cosmetic composition for improving skin condition containing cypress extract | |
KR20190020946A (en) | A composition for preventing or improving skin wrinkle comprising herb extracts or fermentation products thereof | |
KR101189794B1 (en) | Composition for external application to the skin containing Hibiscus cannabinus extract | |
KR102386120B1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
KR20050026806A (en) | Cosmetic composition containing jujube extract | |
KR100467081B1 (en) | Cosmetic Composition for Improving Skin Wrinkles Comprising Bergenia Emeiensis as Active Ingredient | |
KR20080060380A (en) | Cosmetic composition for preventing skin aging containing broccoli extract as an active ingredient | |
KR20100011170A (en) | Skin care cosmetic composition | |
KR100946584B1 (en) | Cosmetic composition for astringent and skin irritation containing fruit extract and Blue Lotus extract | |
KR20080046793A (en) | Cosmetic composition for improving skin wrinkles containing longan extract as an active ingredient | |
KR20210059517A (en) | Quadruple complex and the composition ratio using Moringa Oleifera Oil, Vitellaria Nilotica (Shea) Butter, Centella Asiatica Extract, Glycyrrhiza Uralensis Extract for maximizing atopic dermatitis improvement and preventive efficacy | |
KR20150057335A (en) | Composition for covering body odor comprising extract of korean fir | |
KR102496500B1 (en) | Cosmetic composition comprising hydroxydecyl ubiquinone, vegetable squalane and natural mixed extract, and method for preparing the same | |
KR20200073523A (en) | Cosmetic Composition for Improving Skin Wrinkle Contaning the Extract of Lithospermum Erythrorhizon | |
JPH0769843A (en) | Hair growing agent | |
KR20090073632A (en) | Cosmetic composition for alleviating skin irritation containing Yeok wood extract and licorice extract | |
KR102148095B1 (en) | Cosmetic composition for anti-aging or anti-wrinkle comprising epidermal growth factor, sericin, Foeniculum vulgare extract and Eugenia caryophyllus extract | |
KR20050026807A (en) | Cosmetic auxiliary substance comprising jujube extract and licorice extract for alleviating skin irritation | |
KR20180096094A (en) | A composition for improving skin wrinkle comprising Cosmos bipinnatus extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20030909 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050721 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20051129 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20050721 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |